Suppr超能文献

高剂量联合细胞因子治疗的儿科患者化疗诱导中性粒细胞减少症的恢复时间缩短。

Shortened time to recovery from chemotherapy induced neutropenia in pediatric patients with high dose combined cytokines.

作者信息

Deb G, Donfrancesco A, Sio L D, Cozza R, Castellano A, Paole F, Helson L

机构信息

Oncology Service, Ospedale Pediatrico Bambino Gesu, Rome, Italy.

出版信息

Anticancer Res. 1998 Jan-Feb;18(1B):489-92.

PMID:9568167
Abstract

Granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) are cytokines which have been extensively administered as monotherapy to patients with a variety of hematopoietic disorders at dosages of 5 mcg/kg/day. Because their spectrum of activity is both singular and simultaneously overlapping, we postulated that combined therapy would be more advantageous than monotherapy. Since 1992 we have carried out a study of G-CSF and GM-CSF as monotherapy or in combination in pediatric patients with solid tumors following chemotherapy induced nadirs of 0-800 WBC/mm3. When combined, the cytokines were given twice per day at 2.5 or 5.0 mcg/kg. For the monotherapy groups, either cytokine at 5 mcg/kg or 10 mcg/kg was given once daily. The mean time to recovery from neutropenia nadir ranged from 6.6-8.2 days in patients receiving a total of 10 mcg/kg/day compared to 10.4-10.6 days in patients treated with 5 mcg/kg/day. Side effects were ephemeral eosinophilia. The dosage of 10 mcg/kg/day appears to be a better dosage for pediatric patients with a slight advantage in the combined twice a day schedule (6.6 days).

摘要

粒细胞集落刺激因子(G-CSF)和粒细胞巨噬细胞集落刺激因子(GM-CSF)是细胞因子,已以5微克/千克/天的剂量作为单一疗法广泛应用于患有各种血液系统疾病的患者。由于它们的活性谱既单一又有重叠,我们推测联合治疗比单一治疗更具优势。自1992年以来,我们开展了一项研究,观察G-CSF和GM-CSF作为单一疗法或联合疗法用于化疗后白细胞计数最低点为0-800/立方毫米的实体瘤患儿。联合使用时,细胞因子以2.5或5.0微克/千克的剂量每天给药两次。对于单一疗法组,以5微克/千克或10微克/千克的剂量每天给药一次。接受总共10微克/千克/天治疗的患者从中性粒细胞减少最低点恢复的平均时间为6.6-8.2天,而接受5微克/千克/天治疗的患者为10.4-10.6天。副作用为短暂性嗜酸性粒细胞增多。10微克/千克/天的剂量似乎对儿科患者是更好的剂量,在每天两次联合给药方案中略有优势(6.6天)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验